Numerous studies have demonstrated that the synergistic blockade of PD-1/PD-L1 with other inhibitory checkpoints significantly improves survival, underscoring the need to explore additional targets to overcome resistance and expand therapeutic options for all forms of breast cancer (12, 50, 51). This evidence concerns the gene CD274 and breast carcinoma.